A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (AG881-C-004)

Grants and Contracts Details

StatusActive
Effective start/end date5/12/205/2/25

Funding

  • Servier Pharmaceuticals LLC: $172,196.00